Get started
Abeona Therapeutics Inc.Abeona Therapeutics Inc.Abeona Therapeutics Inc.

Abeona Therapeutics Inc.

No trades
OverviewFinancialsNewsDocumentsIdeasMindsTechnicalsForecastsSeasonalsOptionsETFs

Market insights

Looking for 10x surge stock, Here it is Abeona Therapeutics Inc. (NASDAQ: ABEO) is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious and life-threatening diseases, with a focus on rare genetic disorders. This company stock has been under performing for past 5 years with decline rate of 99% from its price 5 years ago. The price is range bound for past 4+ years $3 to $5. Major reasons I correlate for the indeed decline are * Allocation of less operational budgets since 2018 * COVID influences on Market * Early-stage biotechs focused on rare disease therapies Why I consider there will be a surge of 10x price hikes 1. After long struggle in the rare disease therapies research , this company succeeded for first time in launching ZEVASKYN® (prademagene zamikeracel, formerly pz-cel): An FDA-approved autologous, cell-based gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare skin disorder. On December 8, 2025, the company reported the first patient treated with ZEVASKYN gene therapy.  2. Several programs in preclinical trials and 6 major programs are in close partnership with other reputed & successful organizations (High chances of FDA approval in clinical trials. 3. Strong Technicals : Price surge testing 50 & 200 of weekly Moving Average and sustained above 50 weekly MA; with 20x surge in volume (2M avg weekly volume to 40M volume). 4. 50 Weekly MA crossover with 200 WMA and about to break out 200 WMA. 5. No known legal/law suits or issues with the company. Higher respect and growth prospects. Overall I am strongly bullish on this. 200 WMA breakout will give a surge of price anywhere from 5x to 10x returns in very short term. 25X to 40X returns in long term. Note: Please do your own study and invest with caution.
NASDAQ:ABEOLong
by bradhakiran
Abeo🔍 Technical Analysis – Daily Chart 🟩 Entry Zone: $5.32 – $5.20 Support Zone: Price is currently sitting within a well-defined support zone (green area), which has acted as a significant demand area in the past (late May and mid-April). This zone shows multiple price reactions, making it a key accumulation area for potential buyers. The candlestick wicks within this area suggest buying pressure is building up. 📈 Potential Reversal & Upside Projection A bullish reversal pattern seems to be forming, with the potential to create a higher low, signaling a possible trend change. The blue projected path indicates a bullish move towards the next resistance zone. 🎯 Target Zone: $6.37 – $6.65 This red resistance zone has acted as a strong supply area, capping price advances multiple times in the past (June, August, early September). A move towards this area would represent a potential upside of approximately 20–25% from the current price range. Watch for selling pressure or consolidation once this zone is approached. 📊 Market Structure The overall structure suggests the price is in a range-bound market, with clear support and resistance levels. The move from support to resistance may form a swing trade opportunity for short- to medium-term traders. 🔧 Key Technical Notes Risk Management: Stop-loss could be considered just below the $5.20 level to protect against breakdowns. Confirmation: Look for bullish reversal patterns (e.g., bullish engulfing, hammer) or increased volume to confirm entry. Trend Shift: A break above $6.65 with volume may indicate a trend reversal to the upside. 🧠 Summary Bias: Short-term bullish within a range. Entry Zone: $5.20 – $5.32 Target Zone: $6.37 – $6.65 Invalidation Level: Below $5.20 This setup offers a favorable risk-to-reward ratio, provided market conditions and volume support the move.
NASDAQ:ABEOLong
by IbrahimTarek
ABEOABEO is currently trading at $5.58 and is expected to pull back toward the green zone to retest the previously broken descending trendline and the strong demand area between $4.75 and $5.08. This zone is considered a key support level, where buying pressure has been historically strong. A successful retest could signal a continuation of the bullish trend. The medium-term target is the red supply zone between $11.39 and $12.69, which represents the next major resistance area. ✅ Entry Zone: $4.75 – $5.08 (demand zone) 🎯 Target Zone: $11.39 – $12.69 (supply zone) ❌ Stop-Loss: $3.90 (below previous key low and invalidation of structure)
NASDAQ:ABEOLong
by IbrahimTarek
ABEO is undervalued; Market has NOT priced in FDA approval news.Looks like a good monthly or longer play for the following reasons: 1. Beginning to see elevated RVOL (although it is Pre) in the hundreds. 2. recent fantastic news, the MAIN drug they are developing received FDA approval, this cannot be understated as a) it makes all previous revenues from quarters irrelevant (as they can now fully market and distribute the treatment, which will fix prior low rev issues, because its an R&D company), b) they were only losing about 40mil a quarter before which again, is actually relatively low compared to other pharma-dev companies (many have like 20mil + burn per quarter). 3. stock is trading at a consolidation region below the gap, for the last few years. (avg range between 3-5$, with some spikes between) 4. managed to stay in the NASDAQ due to a 25/1 reverse split, which many times just continues to crush the company stock, but this one has held steadfast in this lower region for the last three years. 5. Post RS, the price has trended slowly up, with higher lows, and a push back towards the gap, which was rejected in April 2024. Even after this the next lows (May 2024) were still higher, and the rejection from 6.80 region was followed by another higher low (april 2025). Resistance at around 6.80, and next at the bottom of gap fill at 9.00. Price has barely moved with the news, and this appears to be a slow burn up until it does a 15%-20% day and pops up on traders screeners. I'm long on the drop yesterday below 5$. Popped up on my scanner yesterday and will continue to track this trade. We'll see where it goes by Fall. Note: we also saw the HIGHEST VOLUME in about 5 years yesterday. With little price movement, this reeks of institutional movement.
NASDAQ:ABEOLong
by aShiftyLad
1
ABEOABEO stock presents one of the best opportunities in the US market, with target prices well above $100. It is an excellent stock for investors. Currently, the stock is in a weekly upward trend and has broken through a strong supply zone from which it had bounced multiple times before. Now, it is pulling back to test this zone as a demand area, gaining momentum to push higher. The next resistance area above is the red supply zone, and if it breaks through, a new high will be set. The target for the new high ranges from $12.70 to $15-$30. The stock is in the process of forming an inverted head-and-shoulders pattern, which will activate with a break above $9. We are waiting to buy near the range of $5.70 to $4.50,Stop loss 4$, aiming for the higher targets. After reaching $30, we will update the chart.
NASDAQ:ABEOLong
by IbrahimTarek
Abeona Therapeutics Inc.** risky investment opportunity, $200m market capital ** Happy with the risk? On the above 10-day chart price action has corrected a massive 95% from a high of $20 in early 2018. A number of reasons now exist to be bullish. Why? 1) Bullish divergences. Since the ‘great buy’ signal price action has continued to print lower lows while higher lows are printing with the oscillators. The monthly chart below provides a better overall illustration. Currently 7 oscillators are diverging with price action. 2) RSI resistance. After an extensive period RSI has broken resistance. This is clearly visible on both 10-day and monthly charts. 3) Volume. On the 3-month chart (bottom) volume continues to flow in as price action dips. I’ve not idea why, someone knows something I don’t. Follow the money. Is it possible for price action to fall further? For sure. Is it probable? Unlikely. A buy from < $2.80 is excellent. Good luck! WW Monthly chart bullish divergences 3-month chart - volume
NASDAQ:ABEOLong
by without_worries
3
ABEO | Bullish All Year | LongAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
NASDAQ:ABEOLong
by DivergenceSeeker
Watch this one!Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
NASDAQ:ABEOLong
by DivergenceSeeker
$ABEO Next Target PTs .60-1 and higher Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.
NASDAQ:ABEOLong
by BADQOMOCAWGOWLD
1